IDEAYA Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 16, 2026, specifically the 2026 Annual Meeting of Stockholders and subsequent Board of Directors actions. The filing details the results of stockholder votes and changes to corporate governance leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting. As of the record date (April 20, 2026), 87,860,920 shares were outstanding.
- Proposal 1 (Election of Directors): All three Class I nominees were elected.
- Yujiro S. Hata: 70,546,418 votes For; 2,470,077 votes Withheld.
- M. Garret Hampton, Ph.D.: 56,718,637 votes For; 16,297,858 votes Withheld.
- Catherine J. Mackey, Ph.D.: 70,281,521 votes For; 2,734,974 votes Withheld.
- Proposal 2 (Ratification of Auditors): PricewaterhouseCoopers LLP was ratified with 82,579,758 votes For, 141,240 votes Against, and 384,840 Abstentions.
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation passed with 64,269,756 votes For, 8,349,131 votes Against, and 397,608 Abstentions.
Management Commentary and Governance Changes
Effective June 16, 2026, the Board of Directors announced the following leadership changes:
- Yujiro S. Hata was elected as Chairman of the Board.
- Terry Rosen, Ph.D. was elected as the Board's Lead Independent Director.
The filing contains no specific guidance, outlook, or discussion of risks and contingencies beyond the standard governance updates.
Investor Verification Checklist
- Verify the full text of the definitive proxy statement (Schedule 14A) filed on April 29, 2026, for detailed background on the director nominees and executive compensation.
- Confirm the effective date of the new Board leadership roles (Chairman and Lead Independent Director) in subsequent corporate filings.
- Review the upcoming 10-K or 10-Q filings for the financial metrics absent from this 8-K.